Janux Therapeutics, Inc.JANXEarnings & Financial Report
Nasdaq
NextFeb 27, 2026
JANX Q3 2025 Key Financial Metrics
Revenue
$10.0M
Gross Profit
N/A
Operating Profit
$-35.3M
Net Profit
$-24.3M
Gross Margin
N/A
Operating Margin
-352.5%
Net Margin
-243.1%
YoY Growth
2177.9%
EPS
$-0.39
Financial Flow
Janux Therapeutics, Inc. Q3 2025 Financial Summary
Janux Therapeutics, Inc. reported revenue of $10.0M for Q3 2025, with a net profit of $-24.3M (-243.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $10.0M |
|---|---|
| Net Profit | $-24.3M |
| Gross Margin | N/A |
| Operating Margin | -352.5% |
| Report Period | Q3 2025 |
Janux Therapeutics, Inc. Annual Revenue by Year
Janux Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.6M |
| 2023 | $8.1M |
| 2022 | $8.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $1.3M | $8.9M | $439000 | $0 | $0 | $0 | $10.0M |
| YoY Growth | -13.5% | -38.9% | 741.7% | -82.6% | N/A | N/A | N/A | 2177.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $380.4M | $689.0M | $691.4M | $695.0M | $1.06B | $1.05B | $1.03B | $1.02B |
| Liabilities | $36.1M | $33.2M | $33.7M | $38.9M | $38.7M | $38.3M | $41.7M | $48.2M |
| Equity | $344.3M | $655.8M | $657.7M | $656.1M | $1.02B | $1.01B | $990.5M | $976.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.9M | $-14.8M | $-10.0M | $-2.2M | $-16.7M | $-17.0M | $-23.8M | $-12.9M |